TABLE 2.
Parasite and fever clearance times for patients with P. vivax infection in various treatment groups
| Treatment group | Total no. of patients | Parasite clearance times (h)a
|
FCT (h)b
|
|||
|---|---|---|---|---|---|---|
| PC50 | PC90 | PCT | FCTA | FCTB | ||
| CPc | 30 | 15 (11) | 25 (12) | 64 (22) | 9 (2–24) | 30 (4–72) |
| Chloroquine | 30 | 9 (6) | 20 (7) | 65 (18) | 10 (2–30) | 31 (4–60) |
| Primaquine | 30 | 23 (16) | 48 (19) | 93 (34) | 4 (4–44) | 28 (4–96) |
| Quinine | 22 | 15 (8) | 33 (8) | 98 (23) | 8 (4–24) | 31 (6–169) |
| Mefloquine | 20 | 10 (5) | 24 (9) | 76 (22) | 4 (2–19) | 21 (4–39) |
| Halofantrine | 23 | 13 (7) | 37 (12) | 85 (24) | 8 (4–23) | 35 (8–104) |
| Artesunate | 20 | 6 (2) | 9 (3) | 38 (13) | 9 (3–24) | 14 (6–72) |
| Artemether | 20 | 6 (3) | 10 (4) | 50 (11) | 4 (3–25) | 17 (3–114) |
| PS | 12 | 13 (7) | 46 (15) | 114d (44) | 7 (4–16) | 58 (15–>168) |
| Total | 207 | 12 (10) | 28 (17) | 74 (31) | 8 (2–30) | 27 (3–>168) |
a
Data are means (standard deviations).
b
Data are means (ranges).
c
CP, Chloroquine-primaquine.
d
Excluding five patients with treatment failure.